Trial Profile
A Phase II Study of Amrubicin Chemotherapy as First Line Treatment in Patients With Metastatic or Unresectable Soft Tissue Sarcoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Soft tissue sarcoma
- Focus Therapeutic Use
- 22 Feb 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Feb 2016 Results published in the Investigational New Drugs
- 20 Feb 2016 Primary endpoint (To evaluate the response rate for amrubicin in patients with metastatic or advanced sarcoma as first line therapy) has been met, as per the results published in the Investigational New Drugs